

# Curriculum Vita

Raheleh Roudi

Email: [Raheleroudi@gmail.com](mailto:Raheleroudi@gmail.com) / [Roudi@uthscsa.edu](mailto:Roudi@uthscsa.edu)

## ACADEMIC RECORD

- 2009 - 2014**      **PhD, Molecular Medicine**  
*Thesis title:* Comparison of gene expression and protein detection of cancer stem cells (Tumorigenic) with non-tumorigenic lung cancer cells  
*Supervisors:*  
Prof. Zahra Madjd; Iran University of Medical Sciences, Tehran, Iran  
Prof. Marzieh Ebrahimi; Royan Institute for Stem Cell Biology & Technology, Tehran, Iran
- 2007 - 2009**      **MSc, Human Genetics**  
Tabriz University of Medical Sciences  
Tabriz, Iran
- 2001 - 2006**      **BSc, Midwifery**  
Tehran University of Medical Sciences  
Tehran, Iran

## EMPLOYMENT HISTORY

### (a) Research

- 2020 – present**      **Visiting Scientist**  
Oncinfo Lab  
University of Texas Health Science Center at San Antonio  
San Antonio, Texas, USA
- 2015 – 2020**      **Researcher**  
**(Feb)**      Oncopathology Research Center  
Iran University of Medical Sciences  
Tehran, Iran
- 2005 - 2006**      **Researcher**  
Persian Association for Cancer Research  
Tehran University of Medical Sciences  
Tehran, Iran
- 2005 - 2006**      **Researcher**  
Researchers Without Borders Institute  
Tehran, Iran

**2004 - 2005**      **Researcher**  
Rheumatology Research Center  
Tehran University of Medical Sciences  
Tehran, Iran

**(b) Academic**

**2015 – 2020 (Feb)**    **Lecturer and Researcher**  
Iran University of Medical Sciences  
Tehran, Iran

**(c) Clinical**

**2006 - 2007**      **Clinical Midwifery Educator**  
Iran University of Medical Sciences  
Tehran, Iran

### Online Publications (publication date);

1. Saeednejad Zanjani, L., Madjd, Z., Rasti, A., Asgari, M., Abolhasani, M., Tam, K. J., **Roudi, R.**, Mælandsmo, G.M., Fodstad, Ø., Andersson, Y. Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics. *Front Oncol.* 2019 Dec 4;9:1302. doi: 10.3389/fonc.2019.01302.
2. Yazdani, M., Angaji, H., Fathi, Z., Abolhasani, M., Madjd, Z., Roviello, F., **Roudi, R.**, Asgari, M. Relationship between the KLK3 rs17632542 and PRNCR1 rs16901979 polymorphisms and susceptibility to prostate cancer. *Meta Gene.* 2019 Sep; 21; 100595. doi:10.1016/j.mgene.2019.100595 (Corresponding Author)
3. Roviello, G., D'Angelo, A., **Roudi, R.**, Petrioli, R., Mini E. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. *J Oncol*, 2019 Jul 4;2019:5692317. doi: 10.1155/2019/5692317.
4. Tartarone, A., Roviello, G., Lerose, R., **Roudi, R.**, Aieta, M., Zoppoli, P. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. *Future Oncol.* 2019 Jun 25. doi: 10.2217/fon-2018-0868.
5. Mohsenzadegan, M., Peng R. W., **Roudi, R.** Dendritic cell / cytokine-induced killer cell-based immunotherapy in lung cancer: what we know and future landscape. *J Cell Physiol.* 2019;1–13. doi.org/10.1002/jcp.28977 (Corresponding Author)
6. Sun, X., **Roudi, R.**, Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., Li, B., Li, X. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. *BMC Cancer.* 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6.
7. Kalantari, E., Abolhasani, M., **Roudi, R.**, Farajollahi, M. M., Madjd, Z., Asgari, M., Asgariyan, S., Mohsenzadegan, M. Co-expression of TLR- 9 and MMP- 13 is associated with the degree of tumour differentiation in prostate cancer. *Int J Exp Pathol.* 2019 May 14. doi: 10.1111/iep.12314
8. Mansoori, M., **Roudi, R.**, Abbasi, A., Abolhasani, M., Rad, I. A., Madjd, Z. High GD2 expression defines breast cancer cells with enhanced invasiveness. *Exp Mol Pathol.* 2019 May 8. doi:10.1016/j.yexmp.2019.05.001
9. Sadeghi, A., **Roudi, R.**, Mirzaei, A., Mirzaei, AZ., Madjd, Z., Abolhasani, M. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer. *Biomark Med.* 2019 Apr 3. doi: 10.2217/bmm-2018-0337. (Co-first author)

10. Zhou, J. G., Zhong, H., Zhang, J., Jin, S. H., **Roudi, R.**, Ma, H. Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma. *Front. Oncol.* 2019 29 Jan doi: 10.3389/fonc.2019.00078.
11. Korourian, A., Madjd, Z., **Roudi, R.**, Sharifabrizi, A., Soleimani, M. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. *Bratisl Lek Listy.* 2019;120(1):35-39. doi: 10.4149/BLL\_2019\_005.
12. Roviello, G., Corona, S. P., Aieta, M., **Roudi, R.** Could the age and the Gleason Score influence to choose the castration-resistant prostate cancer treatment with novel hormonal therapies before or after chemotherapy? Data from a literature-based meta-analysis. *Cancer Biother Radiopharm.* 2019 Jan 8. doi: 10.1089/cbr.2018.2702. (Corresponding Author)
13. Li, F., Liu, G., **Roudi, R.**, Huang, Q., Swierzy, M., Ismail, M., Zhao, S., Rueckert, JC. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. *BMJ Open.* 2018 Sep 10;8(9):e022161. doi: 10.1136/bmjopen-2018-022161. (Co-first author)
14. Fathi, Z., Mousavi, SAJ., **Roudi, R.**, Ghazi, F. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. *PLoS One.* 2018 Jul 26;13(7):e0200633. doi: 10.1371/journal.pone.0200633. (Corresponding Author)
15. **Roudi, R.**, Wang, LZ., Wang, L., Loh, M., Huang, Y., Ou, SHI., Soong, R., Drilon, A., Wee, I., Syn, NLX. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol (Protocol). *Cochrane Database Syst Rev* 2018. DOI: 10.1002/14651858.CD013009.
16. Fathi, Z., Syn, NL., Zhou, JG., **Roudi, R.** Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention. *J Hum Genet.* 2018 Apr 18. doi: 10.1038/s10038-018-0450-y. (Corresponding Author)
17. Lam, WS., Wang, LZ., **Roudi, R.**, Yong, WP., Syn, NL., Sundar, R. Resisting resistance to cancer immunotherapy. *Thorac Cancer.* 2018 Mar 7. doi: 10.1111/1759-7714.12614.
18. **Roudi, R.**, Nemati, H., Rastegar, MM., Sotoudeh, M., Narouie B, Shojaei A. Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population. *Med J Islam Repub Iran.* 2018 Oct 7;32:97. doi: 10.14196/mjiri.32.97.
19. Ranjbar, R., Behzadi, P., Najafi, A., **Roudi, R.** DNA Microarray for Rapid Detection and Identification of Food and Water Borne Bacteria: From Dry to Wet Lab. *Open Microbiol J.* 2017 Nov 30;11:330-338. doi: 10.2174/1874285801711010330.
20. Zhu, J., Li, R., Tiselius, E., **Roudi, R.**, Teghararian, O., Suo, C., Song, H. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or

radiotherapy with curative intent. *Cochrane Database Syst Rev.* 2017 Dec 16;12:CD011300. doi: 10.1002/14651858.CD011300.

21. Sun, X., **Roudi, R.**, Chen, S., Fan, B., Li, HJ., Zhou, M., Li, X., Li, B. Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis. *Medicine (Baltimore).* 2017 Nov;96(44):e8407. doi: 10.1097/MD.0000000000008407.

22. **Roudi, R.**, Syn, NL., Roudbary, M. Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview. *Front Immunol.* 2017 Oct 13;8:1320. doi: 10.3389/fimmu.2017.01320.

23. Kalantari, E., Asadi Lari, MH., **Roudi, R.**, Korourian, A., Madjd, Z. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. *Cancer Biomark.* 2017 Dec 6;20(4):563-573. doi: 10.3233/CBM-170383.

24. Korourian, A., **Roudi, R.**, Shariftabrizi, A., Madjd, Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. *Exp Biol Med (Maywood).* 2017 Dec;242(18):1842-1847. doi: 10.1177/1535370217728460.

25. **Roudi, R.**, Ebrahimi, M., Shariftabrizi, A., Madjd, Z. Cancer stem cell research in Iran: potentials and challenges. *Future Oncol.* 2017 Aug;13(20):1809-1826. doi: 10.2217/fon-2017-0091.

26. Foroozan, M., **Roudi, R.**, Abolhasani, M., Gheytauchi, E., Mehrazma, M. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. *Pathol Res Pract.* 2017 Jun;213(6):612-618. doi: 10.1016/j.prp.2017.04.027. (Co-first author)

27. Roviello, G., Zanotti, L., Cappelletti, MR., Gobbi, A., Dester, M., Paganini, G., Pacifico, C., Generali, D., **Roudi R.** Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? *Clin Exp Med.* 2017 Apr 8. doi: 10.1007/s10238-017-0460-7.

28. **Roudi, R.**, Mohammadi, SR., Roudbary, M, Mohsenzadegan, M. Lung cancer and  $\beta$ -glucans: review of potential therapeutic applications. *Invest New Drugs.* 2017 Aug;35(4):509-517. doi: 10.1007/s10637-017-0449-9.

29. Korourian, A., **Roudi, R.**, Shariftabrizi, A., Kalantari, E., Sotoodeh, K., Madjd, Z. Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness. *Clin Exp Med.* 2017 Nov;17(4):505-517. doi: 10.1007/s10238-016-0443-0.

30. **Roudi, R.**, Madjd, Z., Ebrahimi, M., Najafi, A., Korourian, A., Shariftabrizi, A., Samadikuchaksaraei, A. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. *Tumour Biol.* 2016 Sep;37(9):11843-11859.

31. **Roudi, R.**, Haji, G., Madjd, Z., Shariftabrizi, A., Mehrazma, M. Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer; a tissue microarray analysis. *J Cancer Res Ther.* 2016 Apr-Jun;12(2):1065-9. doi: 10.4103/0973-1482.170940.
32. Sedaghat, S., Gheytauchi, E., Asgari, M., **Roudi, R.**, Keymoosi, H., Madjd, Z. Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. *Appl Immunohistochem Mol Morphol.* 2017 Mar;25(3):196-202. doi: 10.1097/PAI.0000000000000291.
33. **Roudi, R.**, Kalantari, E., Keshtkar, A., Madjd, Z. Accuracy of c-KIT in Lung Cancer Prognosis; a Systematic Review Protocol *Asian Pac J Cancer Prev.* 2016;17(2):863-6.
34. Kalantari, E., Saadi, FH., Asgari, M., Shariftabrizi, A., **Roudi, R.**, Madjd, Z. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. *Appl Immunohistochem Mol Morphol.* 2017 Sep;25(8):592-598. doi: 10.1097/PAI.0000000000000343.
35. Rasti, A., Mehrazma, M., Madjd, Z., Keshtkar, AA., **Roudi, R.**, Babashah, S. Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. *BMJ Open.* 2016 Jan 4;6(1):e009667. doi: 10.1136/bmjopen-2015-009667.
36. Erfani, E., **Roudi, R.**, Rakhshan, A., Sabet, MN., Shariftabrizi, A., Madjd, Z. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes. *Int J Biol Markers.* 2016 Feb 29;31(1):e53-61. doi: 10.5301/jbm.5000165.
37. **Roudi, R.**, Ebrahimi, M., Sabet, MN., Najafi, A., Nourani, MR., Fomeshi, MR., Samadikuchaksaraei, A, Shariftabrizi A, Madjd Z. Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells. *Future Oncol.* 2015;11(17):2383-93. doi: 10.2217/fon.15.174.
38. **Roudi, R.**, Korourian, A., Shariftabrizi, A., Madjd, Z. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes. *Cancer Invest.* 2015;33(7):294-302. doi: 10.3109/07357907.2015.1034869.
39. **Roudi, R.**, Madjd, Z., Korourian, A., Mehrazma, M., Molanae, S., Sabet, MN., Shariftabrizi, A. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. *Cancer Biomark.* 2014;14(6):457-67. doi: 10.3233/CBM-140424.
40. **Roudi, R.**, Madjd, Z., Ebrahimi, M., Samani, FS., Samadikuchaksaraei, A. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. *Cell Mol Biol Lett.* 2014 Mar;19(1):23-36. doi: 10.2478/s11658-013-0112-1.

## REFEREED CONFERENCE PRESENTATIONS

1. **Roudi, R.**, Ebrahimi, M., Madjd, Z. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. The 8th International Iranian Congress of Laboratory and Medicine, Tehran, Iran, Nov 2016 (oral presentation)
2. **Roudi, R.**, Erfani, E., Rakhshan, A., Sabet M. N., Shariftabrizi, A., Madjd, Z. Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes. The 27th Annual meeting of the Arab Division of the International Academy of Pathology (AD-IAP), Dubai, Emirate, Nov 2015 (oral presentation)
3. **Roudi, R.**, Erfani, E., Rakhshan, A., Sabet M. N., Shariftabrizi, A., Madjd, Z. Cancer stem cell markers CD44 and ALDH1A1 are overexpressed in melanoma compared to non-melanoma skin tumors and confer aggressive tumor behavior. The 8th Asian Pacific Organization for Cancer Prevention (APOCP) Regional Conference, Tehran, Iran, Nov 2015 (oral presentation)
4. Mehrazma, M., **Roudi, R.**, Madjd, Z., Haji, G. Evaluation of ALK expression in non-small cell lung cancer: A tissue microarray analysis. The 27th European Congress of pathology Conference in Belgrade, Serbia, Sep 2015 (poster presentation)
5. **Roudi, R.**, Madjd, Z., Korourian, A. Differential expression of cancer stem cell markers ALDH1/CD133 in various lung cancer subtypes. The 1st CSC Conference in Cleveland, USA, Aug 2014 (poster presentation)
6. **Roudi, R.**, Madjd, Z., Korourian, A. Clinical significance of putative cancer stem cell marker, CD44 in different histological subtypes of lung cancer. The 1st CSC Conference in Cleveland, USA, Aug 2014 (poster presentation)
7. Madjd, Z., **Roudi, R.**, Ebrahimi, M., Samadikuchaksaraei, A., Cancer stem cells of human lung adenocarcinoma cell line A549: more specific single marker or new marker combinations? The 8th NCRI cancer conference, Liverpool, United Kingdom, Nov 2012 (poster presentation)
8. **Roudi, R.**, Madjd Z., Korourian A., Molanae, S. Expression of CD44, as a putative cancer stem cell marker, displayed various patterns in different types of lung carcinomas. The 8th NCRI cancer conference, Liverpool, United Kingdom, Nov 2012 (poster presentation)
9. **Roudi, R.**, Madjd, Z., Ebrahimi, M., Samadikuchaksaraei, A., The CD44/24 populations isolated from A549 cell line exhibit similar capacity in vitro studies. The 8<sup>th</sup> Royan International Twin Congress in Tehran, Iran, Sep 2012 (poster presentation)

## GRANT

- Expression of cancer stem cell marker SALL4 and its relationship with clinicopathological features of bladder cancer in patients admitted to Hasheminejad hospital. Iran University of Medical Sciences, 2019.
- Analyzing the results of clinical trials for DC and DC/CIK therapies in patients with lung carcinoma, a systematic review. Iran University of Medical Sciences, 2018.
- Investigation the effects of controlled release antimicrobial peptide indolicidin loaded with biopolymer particles on lung cancer cells. Iran National Science Foundation (INSF), 2018.
- Identification of miR-141 regulatory targets in breast cancer stem cells by a comprehensive proteome analysis and systematic pathway evaluation. Iran University of Medical Sciences, 2018.
- The frequency of the proposed markers of cancer stem cells (SOX2, TWIST2) in colorectal carcinoma in hospitals rasool Firoozgar and Hasheminejad between 1388 to 1394. Iran University of Medical Sciences, 2018.
- Evaluation of beta-glucan extracted from cell wall of candida albicans on lung cancer cells an in vitro. Iran University of Medical Sciences, 2017.
- The frequency of the proposed markers of cancer stem cells (CD44, CD24) in colorectal carcinoma in hospitals rasool Firoozgar and Hasheminejad between 1388 to 1394. Iran University of Medical Sciences, 2017.
- The frequency of the proposed markers of cancer stem cells (Oct4, Nanog) in colorectal carcinoma in hospitals rasool Firoozgar and Hasheminejad between 1388 to 1394. Iran University of Medical Sciences, 2017.
- Evaluation the effect of beta-glucan extracted from the cell wall of Candida albicans, on mesenchymal stem cells and it product effect on mouse lung cancer cells in vitro. Iran University of Medical Sciences, 2017.
- Evaluation of clinical significance of miR-137 and miR-15a and their relation with distinguished colorectal cancer stem cell marker DCLK1. National Institute for Medical Research Development (NIMAD), 2016.
- Evaluating of miR-27a-3p and miR-331-3p expressions as diagnostic biomarker in serum of colon adenocarcinoma and their correlation with prognosis. Iran University of Medical Sciences, 2016.
- Isolation, characterization, animal model (NOD/SCID mice), Telomerase activity, in Renal Cancer stem cells. Iran University of Medical Sciences Joint project with University of Oslo, 2016.
- Molecular Analysis of DDR2 and NF1 and k-RAS Mutations in Squamous Cell Carcinoma of Lung Cancer Samples in Iranian Population, Iran University of Medical Sciences, 2016.



- Evaluation of gene expression level of GPRC6A, E-cadherin and ZEB1 in prostate cancer in comparison to its benign tissues. Iran University of Medical Sciences, 2016.
- Evaluation of miR-372 role in stemness properties of lung cancer cells. Iran University of Medical Sciences, 2016.
- Immunohistochemical expression of chemo resistant markers SMUG1, RhoA, and E2F6 in subtypes of Gastric cancer. Iran University of Medical Sciences, 2016.
- Evaluation of the PI3/AKT signaling pathway using measurement of functional markers FOXO3a and PAK4 in lung cancer samples at the gene and protein levels. Iran University of Medical Sciences, 2015.
- Evaluation of biological characteristics and telomerase activity in cancer stem cells compared with tumor-forming cell population in renal cancer. Iran National Science Foundation (INSF), 2015.
- Investigation of SMAD-4 silencing effect on stemness characteristics of isolated Cancer Stem Cell from Renal Cell Carcinoma in comparison with renal tumor cells population. Iran National Science Foundation (INSF), 2015.

## CONFERENCE SCIENTIFIC COMMITTEE MEMBER

- **19th conference of Pathology and Laboratory Medicine**, Iran University of Medical Sciences, Tehran, Iran, Dec 2017
- **9th conference of International Iranian Congress of Laboratory and Medicine**, Iran University of Medical Sciences, Tehran, Iran, Feb 2017
- **1st symposium of Cancer Stem Cell**, Iran University of Medical Sciences, Tehran, Iran, Feb 2017
- **1st national festival & international congress on stem cell and regenerative medicine**, Iran University of Medical Sciences, Tehran, Iran, May 2016
- **8th conference of International Iranian Congress of Laboratory and Medicine**, Iran University of Medical Sciences, Tehran, Iran, Jan 2016
- **2nd national festival & international congress on stem cell and regenerative medicine**, Iran University of Medical Sciences, Tehran, Iran, Jan 2016
- **2nd conference of Iranian reform progress tissue engineering and medicine**, Iran University of Medical Sciences, Tehran, Iran, Nov 2015
- **17th conference of Pathology and Laboratory Medicine**, Iran University of Medical Sciences, Tehran, Iran, Nov 2015
- **3rd conference of Novel & Innovative Laboratory Technologies**, Iran University of Medical Sciences, Tehran, Iran, Oct 2015

## TEACHING ACTIVITY

1. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran: Teaching of "RNA extraction, cDNA synthesis, and Real-time RT-PCR" for Ph.D by Research (Apr 2019).
2. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran: Teaching of "RNA extraction, cDNA synthesis, and Real-time RT-PCR" for Ph.D by Research (Oct 2018).
3. Iran University of Medical Sciences, Tehran, Iran: Teaching of "Targeting of cancer stem cells" for undergraduate students (Jan 2018).
4. Iran University of Medical Sciences, Tehran, Iran: Teaching of "Targeting of cancer stem cells" for undergraduate students (Sep 2017).
5. School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran: Teaching of "SPSS" for undergraduate students (Apr 2017).
6. School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran: Teaching of "Endnote" for undergraduate students (May 2017).
7. School of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran: Teaching of "Immunohistochemistry" for Ph.D. Molecular Medicine students (Aug 2015).
8. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran: Teaching of "Cell culture, sphere formation assay, colony formation assay, sample preparation for flow cytometry analysis, RNA extraction, cDNA synthesis, and Real-time RT-PCR" for Ph.D by Research (May 2015).
9. School of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran: Teaching of "Basic of nuclear and mitochondrial genomes" for Ph.D. Molecular Medicine students (Mar 2015).
10. School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran: Teaching of "Research Methodology, Proposal Writing & SPSS" for undergraduate students (2012).

## BOOK PUBLICATIONS

Arezoomand, R., Karami F., Alibakhshi, A., Karami, H., Sadeghpour, A., Roudi, R. (2010) *Genetics (Basic, Molecular, Medicine & Genetic Engineering*. Tehran, Khosravi publication

## EDITORIAL POSITION

- Editorial Board Member, Medical Case Reports and Images (2016 - Present)
- Cancer stem cells and lung cancer groups in the Council for Stem Cell Sciences and Technologies were formed in the Iranian Presidential office for Science and Technology (2016 - Present)
- Leader of Cancer stem cells core in Oncopathology Research Center (OPRC), Iran University of Medical Sciences (2016 - Present)

## REFEREE FOR SCIENTIFIC JOURNALS

- Therapeutic Advances in Medical Oncology
- BMC Cancer
- Journal of Cellular Biochemistry
- Tumor Biology
- Biomedicine & Pharmacotherapy
- Cancer Letters
- Future Oncology
- Journal of Thoracic Disease
- Chemico-Biological Interactions
- Plos One
- Pathology - Research and Practice
- Medical Journal of The Islamic Republic of Iran (MJIRI)

## SELECTED AWARDS

- First rank (the highest grade of courses) among MS.c students entrance of 2008
- First rank (the highest grade of courses) among Ph.D. students entrance of 2009

## PROFESSIONAL DEVELOPMENT PROGRAMS

- Courses in "Cancer stem cells isolation and characterization", Royan Institute of the Academic Center for Education, Culture, and Research (ACECR), Tehran, Iran

## IT SKILSS

- High throughput data analysis
- Functional enrichment analysis
- Data analysis with Rev Man software and Stata
- Primer design
- Microsoft Office Suite: Microsoft Word, Microsoft Excel, Microsoft Access, Microsoft PowerPoint and Microsoft Outlook Express,
- EndNote
- SPSS, Syntax

## REFERENCES

### **Professor Ali Samadikuchaksaraei**

Professor of Tissue Engineering & Regenerative Medicine, Iran University of Medical Sciences, Tehran, Iran

Email: Samadikuchaksaraei@yahoo.com

Tel: +982186704714

### **Dr. Ahmad Shariftabrizi**

Instructor in Nuclear Oncology, Division of Nuclear Medicine, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA

Email: Ashariftabrizi@gmail.com

Tel: +18575264145

### **Dr. Ren-Wang Peng**

Group leader, Division of General Thoracic Surgery, Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Email: Renwang.Peng@insel.ch

Tel: +41316324081